Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-142659

Published: 2020

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

Amanda R. Leonti, MS, Laura Pardo, Todd A. Alonzo, PhD, Robert B. Gerbing, Lisa Eidenschink Brodersen, PhD, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, Quy Le, PhD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, John L. Magnani, PhD, William E. Fogler, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 3772.

https://doi.org/10.1182/blood-2019-124525

Published: 2019

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

https://doi.org/10.1182/blood-2019-127100

Published: 2019

Journal Articles

CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia

Tiffany A. Hylkema, BS, Laura Pardo, Keith R. Loeb, MD, Quy Le, PhD, Suzan Imren, MD, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 1444.

https://doi.org/10.1182/blood-2019-126185

Published: 2019

Journal Articles

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531

Laura Pardo, Lisa Eidenschink Brodersen, PhD, Jatinder K Lamba, PhD, Todd A Alonzo, PhD, Yi-Cheng Wang, Dana Paine, Alan S Gamis, MD MPH, E. Anders Kolb, MD, Jessica A. Pollard, MD, Todd M Cooper, DO, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2018) 132 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2018-99-115053

Published: 2018

Journal Articles

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Marianne T. Santaguida, BSc, PhD, Christos Gekas, PhD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Tiffany Hylkema, BS, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 881.

https://doi.org/10.1182/blood-2018-99-115544

Published: 2018

Journal Articles

Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration

Elisabeth R Wilson, Lisa Eidenschink Brodersen, PhD, Barbara Katharina Zehentner, PhD, Andrew J. Menssen, Andrew P. Voigt, Laura Pardo, Denise A. Wells, MD, Johann Hitzler, MD FRCP (C), FAAP, Jason N. Berman, MD, Todd A. Alonzo, PhD, Samir B. Kahwash, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2016) 128 (22): 1687.

https://doi.org/10.1182/blood.V128.22.1687.1687

Published: 2016

Journal Articles

Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

Andrew P. Voigt, Lisa Eidenschink Brodersen, PhD, Robert B. Gerbing, MA, Andrew J. Menssen, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2015) 126 (23): 1377.

https://doi.org/10.1182/blood.V126.23.1377.1377

Published: 2015

Journal Articles

A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531

Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Andrew J. Menssen, Robert B. Gerbing, MA, Laura Pardo, Andrew P. Voigt, Samir B. Kahwash, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2015) 126 (23): 560.

https://doi.org/10.1182/blood.V126.23.560.560

Published: 2015

Journal Articles

Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531

Michael R. Loken, PhD, Andrew P. Voigt, Robert B. Gerbing, MA, Lisa Eidenschink Brodersen, PhD, Andrew J. Menssen, Laura Pardo, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 561.

https://doi.org/10.1182/blood.V126.23.561.561

Published: 2015

Journal Articles

SNP/CGH Microarray Analysis in MDS: Correlation with Conventional Cytogenetic, FISH and Flow Cytometry Findings

Barbara Katharina Zehentner, PhD, Lisa Eidenschink Brodersen, PhD, Christine F Stephenson, PhD, FACMG, Jevon Cutler, Monica E. de Baca, MD, Andrew Menssen, Kelle Hammock, Krystal Johnson, MS, Luise Hartmann, MS, Michael R Loken, PhD, Denise A. Wells, MD

Blood (2014) 124 (21): 5592.

https://doi.org/10.1182/blood.V124.21.5592.5592

Published: 2014

Journal Articles

A Comparative Assessment of Flow Cytometric Scoring Systems in MDS

Lisa Eidenschink Brodersen, PhD, Andrew Menssen, Barbara Katharina Zehentner, PhD, Christine F Stephenson, PhD, FACMG, Monica E. de Baca, MD, Krystal Johnson, MS, Timothy Singleton, MD, Luise Hartmann, MS, Michael R. Loken, PhD, Denise A. Wells, MD

Blood (2014) 124 (21): 5589.

https://doi.org/10.1182/blood.V124.21.5589.5589

Published: 2014

NARROW

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration

Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531

Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531

SNP/CGH Microarray Analysis in MDS: Correlation with Conventional Cytogenetic, FISH and Flow Cytometry Findings

A Comparative Assessment of Flow Cytometric Scoring Systems in MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only